In the News
Haemonetics Announces FDA Approval of PerQseal® Elite Vascular Closure System
Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval of the PerQseal® Elite vascular closure system for large-bore arterial procedures. The approval expands Haemonetics' portfolio of clinically-differentiated large-bore closure devices for structural heart and endovascular procedures in the U.S., following the company's acquisition of Vivasure Medical Limited in January 2026.
The PerQseal Elite system provides sutureless, large-bore vascular closure following structural heart and endovascular procedures performed with 14 – 22F sheaths. Its fully bioabsorbable patch seals arteriotomies up to 26F from within the vessel, enabling near-instantaneous hemostasis and leaving nothing permanent behind. Physicians can confirm hemostasis while maintaining guidewire access, with the flexibility to reposition or recover the system until implant release. Results from the prospective, single-arm, multicenter ELITE arterial study demonstrated 0% major complications per VARC-3 and a mean time to hemostasis of less than one minute.1 In 2025, PerQseal Elite received CE Mark approval in Europe for both arterial and venous indications.
"FDA approval represents an important milestone in our strategy to bolster our presence and growth in advanced vascular closure, with new and meaningful innovation to meet evolving procedural needs," said Jan Hartmann, M.D., Senior Vice President and Chief Medical Officer at Haemonetics. "PerQseal Elite has the potential to further simplify minimally invasive procedures such as TAVR, while supporting patient comfort and experience. We are pleased to offer physicians and their patients in the U.S. this novel, patch-based approach to large-bore vascular closure."
Professor Nicolas van Mieghem, MD, co-investigator of the ELITE study clinical trials and interventional cardiologist at ZOL Hospital in Genk, Belgium, said, "I have found PerQseal Elite to be easy to adopt and intuitive to use, with rapid hemostasis being a particularly notable feature. In both the ELITE study and our early clinical experience, it has integrated well into procedural workflows for large-bore arterial interventions."
Clinical data related to PerQseal Elite will be presented and discussed by Haemonetics at the Transcatheter Cardiovascular Therapeutics® (TCT) Conference at the end of October.
VARC-3 major device-related vascular access site complications through 30 days. See PerQseal® Elite Instructions for Use.
About Haemonetics
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our Apheresis business features proprietary technologies designed to enhance safety, yield, donor satisfaction and operational efficiency for plasma and blood collectors around the world. Our MedSurg business offers Blood Management Technologies designed to help inform treatment decisions and optimize the management of blood products, and Interventional Technologies, including advanced vascular closure systems and sensor-guided technologies, designed to drive procedural effectiveness and elevate the patient experience. To learn more about Haemonetics, visit www.haemonetics.com.
Lenire Now Included in U.S. ENT Clinical Practice Guidelines - First New Treatment Added by American Academy of Otolaryngology Since Establishment of the Academy's Tinnitus Guidelines
The American Academy of Otolaryngology – Head and Neck Surgery Foundation has included Lenire (bimodal neuromodulation) as a treatment option for the first time in their Clinical Practice Guidelines for Tinnitus.
Lenire is the only new treatment recommendation added to the guidelines since its establishment in 2014.
Lenire, by Neuromod Devices, is the first and only FDA-approved bimodal neuromodulation tinnitus treatment device.
The American Academy of Otolaryngology – Head and Neck Surgery Foundation (AAO-HNSF) has included Lenire (bimodal neuromodulation) as a treatment option in the Academy's new Clinical Practice Guidelines for Tinnitus.
Bimodal neuromodulation is the only new treatment recommendation added to the AAO-HNSF guidelines since their establishment in 2014. Building on the FDA's landmark approval of Lenire in 2023 (the first and only bimodal neuromodulation device approved by the FDA), further establishes Lenire as a new standard of care for tinnitus in the U.S.A.
The AAO-HNSF guidelines help ENTs across the United States to clinically evaluate and manage tinnitus in everyday care. The guidelines "emphasize interventions and therapies deemed beneficial" and directs American ENTs "to avoid treatments that are time-consuming, costly, inaccessible, and ineffective".
"This is another historic first for our company, our technology and for the field of tinnitus treatment," said Neuromod Founder, Dr. Ross O'Neill Ph.D. "Lenire being included in the American Academy of Otolaryngology's guidelines, means that the 12,000-plus practicing ENTs in the U.S. now have a new safe and effective treatment to recommend to the tens of millions of Americans suffering from tinnitus."
Robust Evidence Underpins American Academy of Otolaryngology Decision on Lenire
US ENTs can now confidently recommend Lenire knowing that it has been reviewed by the Academy's panel of tinnitus experts.
Lenire combines sound stimulation with mild electrical stimulation to the surface of the tongue (bimodal neuromodulation) to relieve the symptoms of tinnitus. Lenire has been proven effective and inherently safe in three large-scale clinical trials1,2,3 and validated in a growing body of real-world clinical outcomes.4,5
Lenire's landmark FDA Approval in March 2023 was based on the pivotal TENT-A3 controlled clinical trial and confirmatory real-world evidence. The results were published in Nature Communications and is in the 99th percentile most-viewed in articles tracked by Nature.
Since then, tens of thousands of American patients have been successfully treated with Lenire in clinics across the United States. The company plans to support these clinicians to continue to publish this growing body of real-world evidence to firmly establish Lenire as a leading standard of care.
Results in the first peer-reviewed real-world paper published in Nature Communications Medicine reported 91.5% of tinnitus patients had a clinically significant reduction in tinnitus. The second real-world retrospective analysis published in The American Journal of Audiology reported that 81.8% of patients with bothersome tinnitus reported a clinically significant reduction in tinnitus.
"The inclusion of bimodal neuromodulation in the AAO-HNSF Clinical Practice Guideline for Tinnitus reinforces the rigorous and large-scale clinical evidence for Lenire as a treatment for patients seeking help for their bothersome tinnitus" said Neuromod Chief Scientific Officer, Professor Hubert Lim. "Neuromod is committed to further expanding upon the large evidence base for Lenire to make it more effective and accessible for tinnitus patients worldwide."
Lenire is available via qualified healthcare professionals in the United States of America, Canada, Europe, and Australia. It is also a treatment option through the United States of America Veterans Affairs.
About Neuromod Devices
Neuromod Devices is a global medical technology company with offices in Ireland and North America. The company specializes in the design and development of neuromodulation technologies to address the clinical needs of tinnitus patients.
Neuromod has completed extensive clinical trials that confirmed the safety and effectiveness of its non-invasive bimodal neuromodulation tinnitus treatment device, Lenire. For more information about Neuromod, visit www.neuromod.com.
About Lenire®
Lenire® is the first non-invasive bimodal neuromodulation tinnitus treatment device. Bimodal neuromodulation stimulates nerves using two paired stimuli to drive significant relief from tinnitus.
Lenire combines audio stimulation with stimulation to the surface of the tongue that is delivered through a proprietary device trademarked as Tonguetip®.
An appropriately qualified healthcare professional, such as an ENT or audiologist, prescribes Lenire following a comprehensive audiological examination. Patients then complete treatment as advised from the comfort of their own home.
Lenire is backed by the largest volume of clinical research for a tinnitus treatment device. This research has been validated in peer-reviewed and published analyses of tinnitus patients treated with Lenire at independent clinics.
Lenire® has CE-mark certification and is the first and only bimodal neuromodulation to be awarded a De Novo Approval Grant from the US FDA.
References
Conlon et al., Science Translational Medicine, 2020 (TENT-A1)
Conlon et al., Scientific Reports, 2022 (TENT-A2)
Boedts et al., Nature Communications, 2024 (TENT-A3)
McMahan & Lim, Communications Medicine, 2025
Kasper et al., American Journal of Audiology, 2026
Altay Therapeutics Closes $37 Million Series A Financing to Advance First Oral DUX4 Inhibitor for FSHD into the Clinic
DX5057 is an orally administered small molecule designed to inhibit DUX4 transcriptional activity and expression of its targeted proteins
Clinical program will explore DUX4-related biomarkers and muscle function, with a Phase 1 safety study expected to initiate in Q1 2027
Altay Therapeutics, Inc., a biotechnology company developing novel small molecule inhibitors of transcription factors, today announced the completion of a $37 million Series A financing. The round was co-led by Sound Bioventures and HealthCap, with participation from new investors including Fountain Healthcare Partners, Biogen New Ventures, Pappas Capital, and Global BioAccess Fund.
Proceeds from the financing will be used to accelerate the development of Altay’s lead therapeutic candidate, DX5057, through Phase 1 and Phase 2 proof-of-concept clinical trials for patients with FSHD (facioscapulohumeral muscular dystrophy).
"There are no disease-modifying therapies approved for FSHD, and the patient community is in need of a durable, practical solution. DX5057 is an oral medicine that acts systemically to shut down DUX4 at its source,” said James Breitmeyer, M.D., Ph.D., Chief Executive Officer of Altay. “With this financing backed by top-tier life sciences investors as well as past support from SOLVE FSHD, we are on track to initiate clinical development in the first quarter of 2027.”
DX5057 is an orally administered small molecule inhibitor of DUX4 (double homeobox 4), a transcription factor whose aberrant expression in skeletal muscle drives FSHD. DX5057 is expected to distribute freely to all affected muscle and inhibit DUX4 deeply.
“Altay has done the difficult lead discovery and preclinical work and has delivered an oral small molecule candidate on its way into clinical development,” said Ester Sklarsky, M.Sc., of Sound Bioventures. “We co-led this round based on the novel and differentiated approach in FSHD, the strength of the preclinical package, and the team’s strong track record as drug developers.”
“A small molecule-based, disease-modifying therapy could not only make long-term treatment for FSHD practical, but also suppress DUX4 deeply enough to preserve muscle before loss becomes irreversible,” said Carl Kilander, M.D., Ph.D., of HealthCap. “We are excited to support Altay in their mission and during this next phase of growth.”
Ali Ozes, Ph.D., Founder and Chief Scientific Officer of Altay added: “We are especially grateful for the early and essential support from Friends of FSH Research, FSHD Global Research Foundation and SOLVE FSHD that helped us reach this inflection point.”
Since 2022, SOLVE FSHD has invested nearly $7 million in seed financing and provided sustained strategic and Board-level leadership.
In connection with the financing, four new directors will join Altay’s board of directors: Ester Sklarsky, M.Sc., of Sound Bioventures; Carl Kilander, M.D., Ph.D., of HealthCap; Aidan King, MBA, of Fountain Healthcare Partners; and Chelsea Johnson, Ph.D., of Biogen New Ventures. They join Mike Grey, Executive Chairman; Eric Bjerkholt; and James Breitmeyer, M.D., Ph.D., Chief Executive Officer.
About DX5057
DX5057 is an orally available small-molecule investigational product designed to bind double homeobox 4 (DUX4) and inhibit its function, thereby reducing downstream DUX4-regulated gene and protein expression. DUX4 is an embryonic transcription factor that is aberrantly expressed in skeletal muscle of patients with FSHD, where the downstream gene-expression programs it activates are associated with muscle degeneration, impaired regeneration, progressive injury, atrophy, and muscle weakness. In nonclinical pharmacology studies including a transgenic mouse model expressing human DUX4, DX5057 reduced DUX4-associated activity and downstream gene-expression programs, reduced markers of muscle injury, and preserved disease-relevant muscle function. DX5057 has received orphan drug designation from the U.S. Food and Drug Administration.
About FSHD
Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common inherited muscular dystrophies characterized by progressive skeletal muscle weakness and atrophy, typically involving the facial, scapular, and humeral muscles before extending to the trunk and lower extremities. Disease progression occurs over decades and is associated with relentless, irreversible loss of muscle function and increasing disability requiring wheelchair assistance in some cases. With autosomal dominant inheritance, FSHD is associated with increased morbidity and reduced survival. There are currently no approved disease-modifying therapies for FSHD.
About Altay Therapeutics
Altay Therapeutics is a biotechnology company developing novel small-molecule inhibitors of transcription factors. The company’s lead candidate, DX5057, is an orally administered small molecule designed to block DUX4 transcription and degrade the DUX4 protein for the treatment of FSHD. Altay is also developing a STAT3 inhibitor and an ETS family inhibitor with potential across several cancers. Altay’s proprietary discovery platform identifies allosteric binding pockets on transcription factors previously believed to be undruggable and utilizes AI modeling and in silico docking models to identify small molecule antagonists. Backed by marquee investors and led by a team of seasoned drug developers, Altay is driven to turn its discoveries into disease-modifying therapies for patients. For more information, please visit https://www.altaytherapeutics.com.
MMI Raises $125M in Series D to Accelerate Commercial Growth of the Symani Surgical System Worldwide
Financing will support market expansion, expand access, and advance the clinical evidence needed to broaden the role of robotic microsurgery
MMI (Medical Microinstruments, Inc.), a robotics company dedicated to increasing treatment options and improving clinical outcomes for patients with complex conditions, today announced that it has raised $125 million in Series D financing.
The round was led by existing investor BioStar Capital, with participation from new investors S3 Ventures, Angelini Ventures, and an undisclosed strategic corporate investor. MMI’s existing investors also contributed, reflecting strong conviction in the company’s opportunity for continued growth and the expanding adoption of robotic microsurgery globally.
The financing comes as MMI enters its next stage of growth, with approximately 50 installed systems and 3,500 complex microsurgical procedures performed worldwide using the Symani® Surgical System. The capital will support MMI’s continued commercial expansion in the U.S. and key global markets, while strengthening the foundation needed to expand patient access. Investment in clinical trials and outcomes data, including the REMIND study, will also help expand the applications for Symani and support broader adoption.
“We’ve proven there is demand for robotic microsurgery at leading institutions around the world. Now, our focus is translating that adoption into scale,” said Mark Toland, CEO of MMI. “This investment gives us the ability to expand our reach, accelerate adoption and continue advancing the platform through innovation in areas like energy instruments and digital surgery capabilities.”
Scaling Robotic Microsurgery and Advancing New Possibilities
MMI was founded to transform open surgery by extending the capabilities of surgeons at the microsurgical level. As adoption grows, MMI is working with innovation-driven hospitals to develop robotic microsurgery programs designed to bring the capabilities of Symani to more surgeons and patients in need of delicate cancer and trauma-related reconstructive surgery and lymphatic and nerve repair options that improve quality of life.
“We’re excited to lead the oversubscribed round of funding. MMI represents the pinnacle of what we look for at BioStar: a transformational medical technology with the potential to revolutionize patient care and then some,” said Louie Cannon, MD, founder and senior managing director of BioStar Capital. “The most consequential innovations don’t simply improve upon what exists. They create capabilities medicine did not have before. MMI is already demonstrating that in cancer-related lymphedema, and as our scientific understanding of the lymphatic system continues to advance, we believe the company is only beginning to show what those capabilities could mean for patients.”
“The greatest potential for this technology may ultimately lie in areas we are only beginning to investigate,” Toland added. “Through research like REMIND for Alzheimer’s disease, we’re building the evidence and clinical experience that could help define where robotic microsurgery goes next, and the opportunities are remarkable.”
About Medical Microinstruments, Inc. (MMI)
MMI is on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. The company was founded in 2015 near Pisa, Italy, and its proprietary Symani® Surgical System combines the world’s smallest wristed microinstruments with tremor-reducing and motion-scaling technologies to address significant unmet patient needs across the globe. This first-of-its-kind surgical robotic platform for open, soft tissue micro-level surgery can help address microvascular repair and lymphatic repair. In Europe and APAC, it also addresses peripheral nerve repair. The Symani System is authorized for use in the U.S. by the FDA and is a CE Marked medical device in Europe. MMI is backed by global investors including Andera Partners, Angelini Ventures, BioStar Capital, Deerfield Management, Fidelity Management & Research Company, Fountain Healthcare Partners, Panakès Partners, RA Capital, Sambatech, S3 Ventures, and Wellington Partners.
New Senior Commercial Appointments at Neuromod
Joe Ghiz joins Neuromod as Chief Commercial Officer to lead the company's global commercial strategy as they expand access to groundbreaking tinnitus treatment device, Lenire.
Joe Ghiz brings significant experience having held senior global roles at Align Technology, the company behind Invisalign, and Johnson & Johnson.
Shannon Basham joins Neuromod as VP of Channel Development, having most recently serving as Senior Director of Audiology for Sonova Group in the United States of America.
Neuromod Devices has announced the appointment of Joe Ghiz as Chief Commercial Officer (CCO) and Shannon Basham as VP of Channel Development.
Mr. Ghiz joins Neuromod's senior management team and will lead the company's global commercial function, as Neuromod continues to strengthen its position as the category creator in tinnitus care.
Announcing the appointment, Dr. Ross O'Neill, Neuromod CEO commented:
"We are delighted to welcome Joe Ghiz to Neuromod at a pivotal moment where robust clinical evidence, global regulatory approval, and broad commercial adoption has positioned our company for rapid scaling to address the needs of 740 million tinnitus sufferers worldwide. Mr. Ghiz brings experience from Align Technology, where he helped the company create a new category of aligner, which reshaped how orthodontists and dentists practice and built a $10 billion company as a result."
Mr. Ghiz joins Neuromod from Align Technology, the company behind Invisalign.
During his time at Align Technology, Mr. Ghiz played a key role in one of the most significant transformations in modern orthodontics: the development and scaling of the clear aligner category.
As General Manager of Sales and through multiple global commercial leadership positions, he led strategic initiatives that created new avenues for growth, introduced innovative business models, and accelerated market expansion. By working closely with orthodontists and industry partners, he helped drive Invisalign adoption, strengthen practice performance, and advance patient access to more effective and convenient orthodontic care. His contributions supported rapid global growth and reinforced Align Technology's leadership in the digital transformation of orthodontics.
Mr. Ghiz's experience in establishing a new treatment model within dental and orthodontic practices aligns with Neuromod's goal of positioning Lenire as a new standard of care for tinnitus in ENT and audiology practices.
Prior to Align Technology, Joe spent over a decade at Johnson & Johnson Vision Care where he held leadership roles spanning sales, marketing, and business development. He worked extensively with independent optometrists to accelerate practice growth, improve patient outcomes, and increase access to vision care services. In addition, he led initiatives that advanced the ACUVUE® brand's market leadership, helping position J&J Vision Care as an industry leader.
Commenting on his appointment as CCO, Joe Ghiz said:
"I'm excited to join Neuromod at such an important time in the company's growth. Lenire has already transformed the lives of tens of thousands of tinnitus patients and has the potential to revolutionize tinnitus care as a whole. I look forward to working with Neuromod's leadership team to deliver the commercial strategy required to reach more clinicians and give millions of patients access to life-changing care."
In addition to Joe Ghiz appointment as Chief Commercial Officer, Shannon Basham has joined as Neuromod's VP of Channel Development. Shannon has more than 20 years of experience in the hearing care industry, having most recently served as Senior Director of Audiology for Sonova Group in the United States of America.
As Sonova's Senior Director of Audiology and Education, Shannon was the market-facing head of audiology for Phonak and Unitron wholesale businesses where she led the strategy and vision for the audiology and clinical education departments.
Prior to her role as Senior Director of Audiology and Education, Shannon spent a decade as the Director of Clinical Training for Phonak. In this role, Shannon was responsible for content development, management, implementation and communication of training and education programs supporting all Phonak product lines. Additionally, Shannon collaborated with the marketing, clinical and sales departments on messaging that highlighted the features of product performance, consumer benefits and dispensing benefits, which supported the realisation of corporate sales objectives.
Shannon joined Phonak from Insound Medical. As InSound's Clinical Training Manager, Shannon was responsible for the management of the national training team and educational content. Shannon collaborated with marketing, clinical, and sales leadership to commercialize and scale InSound's Lyric Hearing Aid which supported InSound's acquisition by Sonova.
About Neuromod Devices
Neuromod Devices is a global medical technology company with offices in Ireland and North America. The company specialises in the design and development of neuromodulation technologies to address the clinical needs of tinnitus patients.
Neuromod has completed extensive clinical trials that confirmed the safety and effectiveness of its non-invasive bimodal neuromodulation tinnitus treatment device, Lenire. For more information about Neuromod visit www.neuromod.com.
About Lenire®
Lenire® is the first non-invasive bimodal neuromodulation tinnitus treatment device. Bimodal neuromodulation stimulates nerves using two paired stimuli to drive significant relief from tinnitus.
Lenire combines audio stimulation with stimulation to the surface of the tongue that is delivered through a proprietary device trademarked as Tonguetip®.
An appropriately qualified healthcare professional, such as an ENT or audiologist, prescribes Lenire following a comprehensive audiological examination. Patients then complete treatment as advised from the comfort of their own home.
Lenire is backed by the largest volume of clinical research for a tinnitus treatment device. This research has been validated in peer-reviewed and published analyses of tinnitus patients treated with Lenire at independent clinics.
Lenire® has CE-mark certification and is the first and only bimodal neuromodulation to be awarded a De Novo Approval Grant from the US FDA.
Lenire is available in the United States of America, Canada, Europe, and Australia. It is also a treatment option through the United States of America Veterans Affairs.
Neurent Medical Secures €25 Million Growth Debt Facility from Claret Capital Partners to Accelerate Commercial Expansion
Neurent Medical, the pioneer behind the NEUROMARK® System for the treatment of chronic rhinitis, today announced that it has secured a €25 million growth debt financing facility from Claret Capital Partners.
The financing will support the continued commercial expansion of NEUROMARK®, accelerate investment in sales and marketing initiatives, strengthen the company's balance sheet, and provide additional capital to support future growth opportunities.
The financing follows Neurent Medical's successful €62.5 million Series C financing completed earlier this year, further reinforcing the company's position as a leader in minimally invasive treatments for chronic inflammatory sinonasal diseases.
Brian Shields, CEO of Neurent Medical said: "This financing represents another important milestone for Neurent Medical as we continue to scale our commercial operations and expand patient access to NEUROMARK. We are delighted to deepen our relationship with Claret Capital Partners, whose continued support reflects confidence in our technology, clinical evidence, commercial progress and long-term vision. The facility provides significant financial flexibility while allowing us to continue executing our growth strategy with minimal dilution to shareholders."
Daniel Mallon, Principal at Claret Capital Partners comments: "Neurent Medical has demonstrated exceptional progress in establishing NEUROMARK as a leading treatment option for chronic rhinitis. We are pleased to further support the company as it continues its commercial expansion and works to improve outcomes for millions of patients suffering from chronic rhinitis."
About Neurent Medical
Neurent Medical is dedicated to transforming the treatment landscape for chronic inflammatory sinonasal diseases. Its flagship NEUROMARK® System utilizes proprietary impedance-controlled radiofrequency technology to target hyperactive posterior nasal nerves, offering durable relief from chronic rhinitis symptoms. The company is headquartered in Galway, Ireland, with U.S. operations in Braintree, Massachusetts.
For more information visit www.neurentmedical.com
About Claret Capital Partners
Claret Capital Partners is Europe's largest independent growth debt fund manager. Since 2013, the firm has invested over €1.5bn through its funds, supporting more than 210 companies across the technology, life sciences and impact sectors. Its team has been active in investing into European companies for over 25 years, providing innovative debt solutions that help entrepreneurs and their investors grow their companies while minimising dilution.
For more information visit www.claret-capital.com
Priothera Appoints Experienced Biotech Executive, Dr Nigel Clark, as Chief Business Officer to Lead Strategic Partnering for Mocravimod
Priothera is the only company in advanced clinical development with a potential maintenance treatment for patients with acute myeloid leukaemia undergoing allogeneic hematopoietic cell transplantation
Priothera, a late-stage clinical biopharmaceutical company developing mocravimod, an orally applied sphingosine 1-phosphate (S1P) receptor modulator for haematological malignancies, announces the appointment of Nigel Clark, PhD, as Chief Business Officer (CBO).
Dr Clark brings more than 25 years of commercial and strategic leadership experience across the biotechnology and pharmaceutical industries, with particular expertise in business and corporate development, licensing, M&A and transaction execution. In his new role, he will work closely with Priothera's leadership team to maximise the commercial potential of mocravimod and lead efforts to secure strategic partnership opportunities with global pharmaceutical and biotechnology companies.
Mocravimod is currently being evaluated in a pivotal international Phase 3 study (MO-TRANS) in patients with Acute Myeloid Leukaemia (AML) undergoing allogeneic hematopoietic cell transplantation (allo-HCT). This unique oral therapy is designed to increase the graft-versus-leukaemia (GvL) effect with the potential to improve the relapse and survival outcomes for patients following transplant. Priothera is the only company in advanced clinical development with a potential maintenance treatment for AML patients undergoing allo-HCT.
Florent Gros, Co-Founder and CEO of Priothera, commented, "Welcoming Nigel to our leadership team comes at an important stage for Priothera as we advance mocravimod through pivotal Phase 3 development. His extensive track record in business development and executing major strategic transactions will be invaluable as we engage with potential partners to maximise the value of mocravimod and, ultimately, its potential to reach patients who need new treatment options."
Prior to joining Priothera, Dr Clark served as CBO of Nucleome Therapeutics. Previously, he was Senior Vice President of Business Development and a member of the executive team at Kymab, which was acquired by Sanofi in 2021 for $1.1 billion upfront and up to $350 million in milestones. Earlier in his career, he served as CBO of Syntaxin, which was acquired by Ipsen, and held senior business development roles at Vernalis, Ribotargets and British Biotech. Over the course of his career, Dr Clark has negotiated and executed more than 20 major transactions.
Dr Nigel Clark, Chief Business Officer of Priothera, said, "Mocravimod is a particularly compelling late-stage opportunity, with a differentiated mechanism and the potential to address the significant challenge of relapse following allo-HCT in AML. With the programme advancing through pivotal Phase 3 development, I am excited to join Priothera at this important stage and look forward to engaging with prospective partners to help realise mocravimod's potential for patients."
About mocravimod
Mocravimod is a synthetic S1P receptor modulator being developed for the adjunctive and maintenance treatment of AML to enhance the curative potential of allo-HCT. Mocravimod's unique mechanism of action increases the graft-versus-leukaemia (GvL) effect, critical for eliminating cancer. This novel treatment approach -- mocravimod being the only S1P receptor modulator in development to treat blood cancers -- tackles a high unmet medical need and aims to improve treatment outcomes and patients' quality of life.
About Priothera
Priothera is a late-stage biopharma company pioneering the development of mocravimod, a potential new standard of care in hematologic cancers, in addition to cellular therapies such as allo-HCT and CAR-T cell therapies. Mocravimod is being developed as an adjunctive and maintenance therapy for haematological malignancies requiring allogeneic hematopoietic cell transplantation (allo-HCT), focusing initially on acute myeloid leukaemia (AML). Mocravimod is currently the only treatment with the potential to increase the graft's anticancer effect against leukaemia (Graft-versus-Leukaemia, or GvL), thereby enhancing the curative potential of allo-HCT.
Founded in 2020, Priothera operates in France, with headquarters in Dublin. The company is led by a highly experienced management team with deep expertise in haematology, oncology, immunology and cell-based therapies. Priothera is backed by leading international life sciences investors.
MMI Receives FDA Approval to Advance to Phase II of Patient Enrollment in Groundbreaking REMIND Microsurgical Study in Alzheimer’s Patients
FDA-approved supplement advances early feasibility study (EFS) toward full enrollment
MMI (Medical Microinstruments, Inc.), a robotics company dedicated to increasing treatment options and improving clinical outcomes for patients with complex conditions, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplement to its Investigational Device Exemption (IDE) for the REMIND study, after review of 30-day safety data for the first round of patients treated. This approval allows expansion of patient enrollment beyond the initial cohort of up to five patients to the full EFS population of 15 patients as the study continues to explore the potential of robotic-enabled microsurgical intervention for neurodegenerative diseases, including Alzheimer’s disease.
The REMIND study (Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease), a global, prospective early feasibility study, is collecting safety and feasibility data of the Symani® Surgical System and microsurgical techniques used to re-establish lymphatic drainage pathways in the deep cervical lymph nodes (dCLNs) of patients with Alzheimer’s and confirmed lymphatic abnormalities.
“Patient safety is paramount, and we’re pleased with this important step forward by the FDA, which allows us to continue expanding enrollment in this first-of-its-kind study,” said Adnan Siddiqui, MD, PhD, Professor of Neurosurgery at the State University of New York at Buffalo, CEO of The Jacobs Institute, and National PI of the REMIND study.
“This milestone reflects continued momentum for REMIND as we explore the potential of microrobotic surgical intervention to reshape the treatment of Alzheimer’s disease for the millions of people and their families impacted by this debilitating disease,” added Mark Toland, CEO of MMI.
As enrollment continues, data generated through REMIND is expected to inform future research, including the potential for a larger pivotal trial. REMIND is one of several studies underway at MMI aimed at building the clinical evidence needed to support the advancement of robotic microsurgery into additional and emerging applications. To learn more, visit www.mmimicro.com.
The safety and effectiveness of the Symani® Surgical System for lymphatic reconstruction for brain disease has not been established by the U.S. Food and Drug Administration, and Symani remains investigational for this use.
About Medical Microinstruments, Inc. (MMI)
MMI is on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. The company was founded in 2015 near Pisa, Italy, and its proprietary Symani® Surgical System combines the world’s smallest wristed microinstruments with tremor-reducing and motion-scaling technologies to address significant unmet patient needs across the globe. This first-of-its-kind surgical robotic platform for open, soft tissue micro-level surgery can help address microvascular repair and lymphatic repair. In Europe and APAC, it also addresses peripheral nerve repair. The Symani System is authorized for use in the U.S. by the FDA and is a CE Marked medical device in Europe. MMI is backed by global investors including Fidelity Management & Research Company, Andera Partners, BioStar Capital, Deerfield Management, Fountain Healthcare Partners, Panakès Partners, RA Capital, Sambatech, and Wellington Partners.
MMI Earns Gold Edison Award for Symani(R), Recognized for Expanding Access to Life-Changing Surgical Treatment Options
MMI (Medical Microinstruments, Inc.), a robotics company dedicated to expanding treatment options and improving outcomes for patients with complex conditions, today announced its Symani(R) Surgical System has earned the top award in the 2026 Edison Awards in the Health, Medical and Biotech category.
Widely regarded as one of the world's top honors for innovation, the Edison Awards recognize technologies that are fundamentally transformative, create meaningful real-world impact, and improve human lives on a global scale. MMI has earned the coveted Edison title for helping expand patient access to complex microsurgical procedures that historically have been out of reach through robotic-assisted microsurgical technology.
For the estimated 10 million Americans living with lymphedema -- including approximately one in three breast cancer survivors -- treatment has often meant lifelong symptom management rather than restoration. Symani is helping change that.
Surgically repairing the lymphatic system requires reconnecting vessels as small as 0.1 millimeters in diameter, and fewer than 600 surgeons worldwide are trained to manually perform lymphatic surgery due to the technical difficulty of the procedure. While millions of patients could potentially benefit from surgical intervention, many have had to solely rely on full-time compression garments and massage therapy to manage chronic swelling, pain, and reduced mobility that significantly impacts quality of life due to limited access to surgical treatment options.
Symani is the only robotic platform of its kind designed specifically for the scale and complexity of open microsurgery -- helping expand surgeon microsurgical and supermicrosurgical capabilities. The system extends precision and control beyond the natural limitations of the human hand, helping more surgeons operate on microscopic anatomy with greater precision, stability, and accuracy. Symani's novel technology and surgical instruments are helping transform microsurgery from a highly specialized, restricted capability into a more accessible treatment option for patients in need.
"Symani is fundamentally changing the way complex conditions are treated, " said Mark Toland, CEO of MMI. "For decades, surgeons performing these procedures lacked meaningful technology advancements despite operating on some of the smallest and most delicate anatomy. "We're proud to help advance microsurgical innovation in ways that bring new treatment possibilities designed to improve quality of life to patients around the world."
Building on its growing use in treating conditions such as cancer-related lymphedema, MMI is exploring how these same techniques may be applied to other regions of the body where unmet medical needs persist. MMI's FDA-approved IDE REMIND study is currently investigating whether supermicrosurgical techniques can be applied to restore lymphatic drainage pathways in the head and neck, with the goal of exploring their potential role in diseases such as Alzheimer's.
About MMI
MMI is on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. The company was founded in 2015 near Pisa, Italy, and its proprietary Symani(R) Surgical System combines the world's smallest wristed microinstruments with tremor-reducing and motion-scaling technologies to address significant unmet patient needs across the globe. This first-of-its-kind surgical robotic platform for open, soft tissue micro-level surgery can help address microvascular repair and lymphatic repair. In Europe and APAC, it also addresses peripheral nerve repair. The Symani System is authorized for use in the U.S. by the FDA and is a CE Marked medical device in Europe. MMI is backed by global investors including Fidelity Management & Research Company, Andera Partners, BioStar Capital, Deerfield Management, Fountain Healthcare Partners, Panakès Partners, RA Capital, Sambatech, and Wellington Partners.
Exciva appoints distinguished biopharma leaderMark Altmeyer as chairman of the board
Strategic appointment underscores Exciva’s ambition to advance Deraphan, its lead product to treat agitation in Alzheimer’s patients, through late-stage development and global expansion
Exciva GmbH, a biopharmaceutical company developing novel therapeutic compounds for the treatment of neuropsychiatric conditions, today announces the appointment of Mark Altmeyer as chairman of its board of directors.
Mark Altmeyer is a biopharmaceutical executive and board leader with over 35 years of experience in commercialization strategy, M&A and international expansion. Since 2014, he has served on the board of ten biopharmaceutical firms across the US, Europe and Japan, including as chairperson of several high-growth biotech companies. His executive roles include president and CEO of clinical-stage companies focused on fibrosis, inflammation, CNS disorders and other neurological therapeutic areas. Key accomplishments include serving as founder and CEO of Arvelle Therapeutics, where, within two years he led the company’s transatlantic build-out, secured $200 million in financing and successfully completed its $1 billion acquisition by Angelini Pharma. Throughout his career, Altmeyer has delivered growth and enterprise value across diverse therapeutic areas and business models, from primary care and specialty pharma to rare diseases and hospital-driven markets, by building high-performing teams and aligning investors and management around clear value-creation priorities.
In addition to his executive experience, Altmeyer brings extensive board-level leadership across the biotech lifecycle, from early-stage development through to late-stage growth and exit.
"Mark's appointment as chairman marks a pivotal moment in Exciva's development. As we advance Deraphan into its Phase 2 trial, his unparalleled experience in commercialization and international expansion provides exactly the strategic guidance we need,” said François Conquet, CEO of Exciva. “His track record in aligning investors and management to drive enterprise value will help us push our symptomatic treatment option for patients with Alzheimer’s disease (AD).”
Deraphan is Exciva’s lead candidate for treating agitation in patients with AD. It is the combination of two clinically validated products, including one novel chemical entity (NCE), which have demonstrated activity in the CNS field, with the potential to offer better efficacy and risk/benefit ratio compared to existing therapies. The clinical trial is being conducted in the UK, US, Canada and Europe. A Phase 1 trial with Deraphan has been successfully completed and showed that the combination is safe and well-tolerated.
“I'm excited to join Exciva at such an important inflection point. The company's innovative approach to addressing neuropsychiatric conditions, particularly with Deraphan's potential to improve outcomes for AD patients experiencing agitation, represents a genuine unmet medical need,” said Mark Altmeyer. “I look forward to working alongside François and the entire team to accelerate clinical development and bring these therapies to patients globally.”
This appointment follows the company’s recent closing of a €53 million ($62M) Series B financing round led by Gimv and EQT Life Sciences. Currently on its board of directors are Raphaël Wisniewski (Andera Partners), Philip Scheltens (EQT Life Sciences), Christoph Kocher (Gimv), Aidan King (Fountain Healthcare), Vikram Sudarsan (independent board member) and François Conquet (CEO).
About Exciva
Exciva is a biopharmaceutical company founded in 2016 by Drs. Anton Bespalov, Hans Moebius and Rao Vepachedu to address neuropsychiatric symptoms in AD dementia and other brain disorders. It uses its powerful discovery potential, which has led to the combination of two CNS-active compounds, to treat agitation in patients living with AD dementia. Exciva is based in Heidelberg, Germany.
MMI’s Symani Surgical System Treats First Alzheimer’s Patient in Groundbreaking REMIND Study
FDA-IDE approved study enrolls first patient for robotic-assisted surgical intervention for neurodegenerative disease
MMI (Medical Microinstruments, Inc.), a robotics company dedicated to expanding treatment options and improving outcomes for patients with complex conditions, today announced completion of the first robotic-assisted procedure in REMIND, its U.S. Investigational Device Exemption (IDE) Study, evaluating microsurgical intervention for neurodegenerative disease. Performed by a multidisciplinary team at Baptist Health in Jacksonville, FL, the case represents the study’s inaugural procedure and first patient enrollment – a participant with moderate Alzheimer’s disease with confirmed abnormalities in their deep cervical lymph node (dCLN) region.
The first-of-its-kind trial, approved by the U.S. Food and Drug Administration (FDA), is evaluating the safety and feasibility of the Symani® Surgical System to perform microsurgical techniques in the region of the neck. The multi-center study will enroll 15 patients who will be followed through twelve months post procedure.
“This is a historic first and important step in advancing a potential breakthrough intervention for neurodegenerative disease,” said Mark Toland, CEO of MMI. “By evaluating novel microsurgical robotic techniques, we’re building on a decade of global research that moves science closer to what could become a life-changing treatment option for the tens of millions of Alzheimer’s patients and caregivers globally.”
The procedure, performed using Symani, explores whether restoring lymphatic drainage pathways in the dCLNs may support improved clearance of harmful neurotoxins that scientific researchers believe contribute to the progression of Alzheimer’s disease. Symani is the only commercially available robotic platform designed specifically for high-precision microsurgical and supermicrosurgical procedures.
This novel approach brings together a dedicated team of specialists with expansive areas of expertise across reconstructive microsurgery, neurology, neuroradiology, and neurosurgery, reflecting the uniquely collaborative effort required to explore new, emerging treatment pathways for complex neurodegenerative diseases.
Dr. Michael DeFazio, Plastic & Reconstructive Surgeon with Florida Plastic Surgery Group, who specializes in the surgical treatment of lymphedema, performed the procedure, with Ricardo Hanel, MD, PhD, Co-Medical Director of Baptist Stroke & Cerebrovascular Center at Baptist Health in Jacksonville, REMIND site PI, and member of the Federal Alzheimer’s Advisory Council as co-surgeon. Dr DeFazio commented “I’m honored to join this effort in exploring how robotic lymphovenous bypass at the supermicrosurgical level can be applied in a new clinical context. Precision is paramount in such technically demanding procedures, and this robotic technology enables us to perform techniques with the control needed to explore this potential new and exciting application of lymphatic reconstruction.”
Dr. Hanel added, “The intersection of neuroscience and lymphatic biology is one of the most compelling frontiers in medicine today. By participating in this study, we’re accelerating beyond traditional research to explore how a surgical approach can open the door to exciting therapeutic pathways in neurodegenerative disease. This opens an exciting window of hope for all those patients and families living with this terrible condition.”
Matthew A. Zuino, MSIS, FACHE, president and CEO of Baptist Health in Jacksonville said, “With Alzheimer’s disease impacting over 580,000 patients and families across Florida, we believe it’s our responsibility to advance potential new approaches that drive progress and expand access to treatments for those who need it most. We are proud to be bringing the next generation of treatments to the region while contributing to the development of innovative therapies globally.”
Michael A. Mayo, DHA, FACHE, Baptist Health’s former president and CEO is also a member of the Federal Alzheimer’s Advisory Council and played a key role in bringing the technology and research to the health system.
As enrollment continues, data generated through REMIND is expected to inform future research, including the potential for a larger pivotal trial. REMIND is one of several studies underway at MMI aimed at building the clinical evidence needed to support the advancement of robotic microsurgery into additional and emerging applications.
The safety and effectiveness of the Symani Surgical System for lymphatic reconstruction for brain disease have not been established by any regulatory agency.
About REMIND
The early feasibility study, entitled REMIND, Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease, is an FDA-approved investigational clinical trial evaluating the use of robotic-assisted microsurgical techniques in the exploration of potential treatment pathways for Alzheimer’s disease. The study builds upon emerging scientific evidence on the role of glymphatic pathways in neurological disease and leverages the precision capabilities of MMI’s Symani® Surgical System. The primary endpoint of the study is device-related serious adverse events through 30 days post procedure. Additional endpoints include adverse events, biomarker and imaging changes, and cognitive assessments through 12 months post procedure.
About Medical Microinstruments, Inc. (MMI)
MMI is on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. The company was founded in 2015 near Pisa, Italy, and its proprietary Symani® Surgical System combines the world’s smallest wristed microinstruments with tremor-reducing and motion-scaling technologies to address significant unmet patient needs across the globe. This first-of-its-kind surgical robotic platform for open, soft tissue micro-level surgery can help address microvascular repair and lymphatic repair. In Europe and APAC, it also addresses peripheral nerve repair. The Symani System is authorized for use in the U.S. by the FDA and is a CE Marked medical device in Europe. MMI is backed by global investors including Fidelity Management & Research Company, Andera Partners, BioStar, Deerfield Management, Fountain Healthcare Partners, Panakès Partners, RA Capital, Sambatech, and Wellington Partners.
Exciva doses first patient in Phase 2/3 trial of Deraphan for agitation in Alzheimer’s disease and extends Series B round
SERENADA trial to run at up to 60 sites across US, UK, Canada and Europe, targeting 300 patients
Exciva brings Series B round to €53M, with Dolby Ventures joining investor pool, and strengthens management with appointment of seasoned COO
Exciva GmbH, a biopharmaceutical company developing novel therapeutic compounds for the treatment of neuropsychiatric conditions, today announces the dosing of the first patient at Esperanza Clinical in Murrieta, CA, USA, in the Phase 2/3 SERENADA trial to evaluate the safety and efficacy of Deraphan in the treatment of agitation in patients with Alzheimer’s disease (AD) dementia.
“We are proud to announce the dosing of the first patient in SERENADA. We are thankful to Dr. Michael Ropacki and the team at Esperanza Clinical for their role in supporting us in developing new treatment options for patients with AD dementia. With its promising therapeutic potential, it could pave the way to treating agitation in other neuropsychiatric disorders,” said François Conquet, CEO of Exciva. “We are equally delighted to welcome Dolby Ventures as a new investor. This growing support reflects the strong confidence in Exciva’s clinical strategy to treat the neuropsychiatric symptoms in AD.”
The behavioral and psychological symptoms of AD dementia can be severe and demanding on caregivers. These include agitation, aggression, sleep disorders, irritability, depression, anxiety and hallucinations. Currently, there are few treatment options available for agitation in patients with AD.
Exciva’s approach in avoiding the dopaminergic system offers the potential to treat agitation without increasing the risk of cognitive decline, morbidity or mortality. If proven effective, Deraphan could become a novel and valuable option in improving the quality of life for patients living with AD.
Deraphan is the combination of two clinically validated products: dextromethorphan, an NMDA receptor channel blocker, and Deramciclane, a triple-acting agent that is a CYP2D6 inhibitor and a 5-HT2A/2C receptor inverse agonist. This combination is designed to deliver a broad and synergistic treatment targeting various neuropsychiatric symptoms associated with dementia, including agitation. Exciva has previously completed a Phase 1 trial of Deraphan, demonstrating that the combination was safe and well-tolerated.
In parallel to the trial launch, Dolby Ventures joins as a new investor, bringing Exciva’s Series B round to a total of €53M ($62M).
“Exciva’s approach to targeting neuropsychiatric symptoms, in particular agitation in Alzheimer's patients, addresses a critical unmet need in Alzheimer’s care,”said Reetika Bhardwaj, principal at Dolby Ventures. “Our investment in Exciva underscores our commitment to advancing therapeutic treatments in neurodegenerative diseases, which have profound societal and economic implications, and providing support for AD patients and carers worldwide.”
Dolby Family Ventures, based in San Francisco (CA), is an early-stage venture capital fund launched in 2014 to honor the legacy of Ray Dolby, philanthropist and founder of Dolby laboratories. It invests in startups specializing in frontier technology that tackle major problems in the life sciences, such as neurodegeneration.
Lastly, Exciva is thrilled to announce the appointment of Nadine Knowles as chief operating officer, further strengthening the executive team. Ms. Knowles brings over 30 years of experience in clinical leadership, with a strong track record of driving strategic initiatives and delivering complex global Phase 1-4 clinical trials and regulatory submissions across rare disease, oncology, CNS (Central Nervous Systems), and anti-infective programs during her time at Avanir (acquired by Otsuka) and Longboard (acquired by Lundbeck).
About the SERENADA Trial
The SERENADA trial (NCT07284472) will enroll approximately 100 patients per treatment arm, around 300 participants in total, at as many as 60 centers across the US, UK, Canada and Europe. Deraphan-treated patients will be compared to a placebo group in a six-week treatment course. The trial will observe behaviors such as restlessness, verbal outbursts, resistance to care or physical aggression as signs of agitation. The objective of the study is to demonstrate that Deraphan, compared to placebo, reduces agitation in AD patients.
Participants will be selected based on a diagnosis of agitation according to its consensus definition in patients with cognitive disorders as developed by the International Psychogeriatric Association (IPA) Agitation Definition Working Group, which must include excessive motor activity, verbal and/or physical aggression. In addition, participants will have a confirmed AD diagnosis proven by a blood biomarker test, such as a plasma-based p-Tau217 assay.
Exciva expects to report the outcome of the study in the first half of 2029.
About Exciva
Exciva is a biopharmaceutical company founded in 2016 by Drs. Anton Bespalov, Hans Moebius and Rao Vepachedu to address neuropsychiatric symptoms in Alzheimer’s disease (AD) dementia and other brain disorders. Exciva uses its powerful discovery potential, which has already led to the combination of two CNS-active compounds, to treat agitation in patients living with AD dementia. Exciva is based in Heidelberg, Germany.
MMI Introduces World’s First Microsurgical Suture for Robotics
New suture expands the Symani ecosystem, supporting greater efficiency and precision in robotic microsurgery
MMI (Medical Microinstruments, Inc.), a robotics company dedicated to increasing treatment options and improving clinical outcomes for patients with complex conditions, today announced the commercial launch in the U.S. of its Robotic Suture. The first suture purpose-built for the Symani® Surgical System represents MMI’s continued innovation in microsurgery and is suitable for cases where delicate suturing is required.
Developed in partnership with Kono Seisakusho Co., Ltd. (Crownjun), a global leader in microsurgical sutures, the Robotic Suture features a shorter suture length and needle enhancements tailored to robotic techniques. It is designed to go beyond traditional suture capabilities with improved handling, streamlined workflow, and delivery of consistent performance during robotic anastomosis.
“While Symani continues to push the boundaries of what’s possible with the human hand at the micro scale, we see a clear path to further enhance surgical performance through technologies optimized for robotic microsurgery,” said Mark Toland, CEO of MMI. “The introduction of advanced technology, such as robotics, is driving continued demand for innovation in microsurgery. The suture expands that ecosystem with a solution that further supports surgeons and their patients with enhanced precision, efficiency, and outcomes.”
“Our role has always been to advance surgery by solving needs at the smallest scale,” said Junichi Kono, President of Kono Seisakusho Co., Ltd. “For years, we have developed microsurgical sutures by listening closely to surgeons and turning highly specialized demands into practical innovation. Together with MMI, we have applied that same philosophy to robotic microsurgery, creating a suture solution that supports greater precision, control, and consistency in demanding procedures.”
Robotic Suture features:
Shorter suture length: Approximately one-third to one-half the length of conventional micro sutures, designed to improve manageability and decrease anastomosis time during complex procedures
Needle curvature options: Two needle curvatures ensure optimal needle angulation for the anatomy with the potential to improve patency and minimize tissue trauma
Direct surgeon loading: Streamlines workflow with easy grasping, particularly in supermicrosurgery cases
Full size range (8-0 to 12-0): Supports all microsurgical and supermicrosurgical applications
Dr. Siba Haykal, MD, PhD, FRCSC, FACS, Section Chief of Reconstructive Oncology and Plastic, Reconstructive and Microvascular Surgeon at Yale New Haven Hospital, was the first to use the new suture in clinical cases earlier this week. “Standard suture needles often have a long curve not ideal for robotic work. Based upon my early experience in supermicrosurgical procedures, the Robotic Suture has better positioning with a curvature that suits the instrument design, making needle passage easier with limited wrist articulation required,” said Dr. Haykal. “The shorter length is key for the robot and for smaller vessels, and these features could help me reduce my overall suture usage. I also see myself using the suture in my manual cases.”
The launch reflects MMI’s strategy to optimize robotic microsurgery with ecosystem-driven innovation. The global market for micro sutures (8-0 and smaller) is estimated at $446 million, with strong growth driven by reconstructive plastic surgery. By introducing a robot-specific suture, MMI aims to broaden its surgical reach and further accelerate adoption of the Symani platform.
The robotic microsurgical suture is commercially available in the United States, with plans to expand into additional markets in the future.
About Medical Microinstruments, Inc. (MMI)
MMI is on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. The company was founded in 2015 near Pisa, Italy, and its proprietary Symani® Surgical System combines the world’s smallest wristed microinstruments with tremor-reducing and motion-scaling technologies to address significant unmet patient needs across the globe. This first-of-its-kind surgical robotic platform for open, soft tissue micro-level surgery can help address microvascular repair and lymphatic repair. In Europe and APAC, it also addresses peripheral nerve repair. The Symani System is authorized for use in the U.S. by the FDA and is a CE Marked medical device in Europe. MMI is backed by global investors including Fidelity Management & Research Company, Andera Partners, BioStar Capital, Deerfield Management, Fountain Healthcare Partners, Panakès Partners, RA Capital, Sambatech, and Wellington Partners.
XyloCor Appoints John Tucker as President and Chief Executive Officer
XyloCor Therapeutics, Inc. (XyloCor or the Company), a clinical-stage biopharmaceutical company focused on developing innovative therapies for cardiovascular disease, today announced the appointment of John Tucker as President and Chief Executive Officer (CEO), effective immediately.
Mr. Tucker brings more than 20 years of leadership experience in the biotechnology and life sciences industries, with a proven track record of advancing clinical programs, building high-performing teams, and driving strategic growth. He succeeds the Company’s current interim leadership, will join the Board of Directors and assumes both roles effective immediately.
“XyloCor is at a pivotal moment in its evolution,” said Mr. Tucker. “With a promising pipeline and a deeply committed team, we are well positioned to transform the treatment landscape for patients with cardiovascular disease. I am honored to lead the Company into its next chapter and look forward to accelerating our clinical programs, strengthening our partnerships and delivering long-term value to both patients and shareholders.”
Glenn Batchelder, Chairman of the Board, welcomed Tucker’s appointment: “John is a dynamic and visionary leader with the operational expertise and strategic insight needed to guide XyloCor through its next phase of development. Following a comprehensive executive search, the Board unanimously agreed that John is the right leader to advance our mission and unlock the potential of our gene therapy platform.”
“John is a proven leader with deep expertise in cardiovascular medicine and a strong track record of building innovative biotechnology organizations,” said Pascal Touchon, Board Member and Operating Partner at Jeito Capital. “His strategic vision, operational discipline and commitment to patients make him exceptionally well suited to lead XyloCor. Under his leadership, the Company is well positioned to further accelerate the development of transformative therapies for patients with cardiovascular disease.”
Prior to joining the Company, Mr. Tucker served as CEO of scPharmaceuticals. Prior to that, he served as CEO of Alcresta Therapeutics. As a leader in the biotechnology space, John has been a central figure in IPO execution, regulatory approvals and commercialization efforts. He brings more than 20 years of experience in leading fundraising initiatives, strategic partnerships and late-stage clinical development programs.
About XyloCor
XyloCor is a private, clinical-stage biotechnology company dedicated to developing potential best-in-class gene therapies designed to address the underlying causes of cardiovascular disease. The Company’s lead product candidate, XC001, is in clinical development for use in patients with coronary artery disease and refractory angina for whom there are no treatment options. The Company, which was co-founded by Ronald Crystal, MD, and Todd Rosengart, MD, has an exclusive license from Cornell University. For more information, visit www.xylocor.com and follow us on LinkedIn.
Neurent Medical Announces Publication of Positive Randomized Controlled Trial Results for the NEUROMARK® System
Study demonstrates superiority of radiofrequency posterior nasal nerve ablation versus sham control in patients with chronic rhinitis
Neurent Medical, a leader in non-surgical treatments for chronic rhinitis, today announced the publication of positive results from its randomized controlled trial (RCT) evaluating the NEUROMARK® System in the International Forum of Allergy & Rhinology. The study demonstrated that treatment with the NEUROMARK System, an impedance controlled radiofrequency ablation device indicated for chronic rhinitis, is superior to sham control in improving nasal symptoms and quality-of-life measures.
The prospective, multicenter, single-blind, superiority RCT randomized 132 participants to either active treatment with the NEUROMARK System or a sham control. The primary endpoint was the comparison of the reflective Total Nasal Symptom Score (rTNSS) responder rate between treatment arms at 90 days. Secondary efficacy outcomes included postnasal drip, chronic cough, Nasal Obstruction Symptom Evaluation (NOSE), mini-Rhinoconjunctivitis Quality of Life Questionnaire (mini-RQLQ), and Patient Health Questionnaire-9 (PHQ-9).
Key findings from the trial include:
The rTNSS responder rate was significantly higher in the active treatment arm (73.3%) compared to the sham control arm (35.0%) (p < 0.001), meeting the primary endpoint and demonstrating superiority of the NEUROMARK System.
Participants treated with NEUROMARK experienced significantly greater improvements in rTNSS, postnasal drip, chronic cough, NOSE score, mini-RQLQ, and PHQ-9 compared to sham control.
NOSE and mini-RQLQ responder rates were significantly higher in the active treatment arm than in the sham control arm.
"These results provide high-level clinical evidence supporting posterior nasal nerve ablation with impedance controlled radiofrequency energy as an effective treatment option for patients suffering from chronic rhinitis," said Mas Takashima, MD, Principal Investigator of the trial and lead author of the publication. "The significant improvements observed across both symptom-based and quality-of-life measures highlight the meaningful impact this therapy can have for patients whose symptoms persist despite medical management."
Brian Shields, Chief Executive Officer of Neurent Medical, added, "The publication of this randomized controlled trial represents another major milestone for Neurent and reinforces our commitment to evidence-based innovation. Demonstrating superiority versus sham in a rigorous RCT underscores the clinical value of the NEUROMARK System and strengthens the foundation for broader adoption of posterior nasal nerve ablation in the treatment of chronic rhinitis."
The NEUROMARK System is designed to deliver multipoint impedance controlled radiofrequency energy to the posterior nasal nerve region, targeting the underlying neural drivers of chronic rhinitis symptoms. Results from this study further support its role as a minimally invasive treatment option for appropriate patients.
About Neurent Medical
Neurent Medical is a medical device company dedicated to developing innovative, non-surgical solutions for patients suffering from chronic rhinitis. The company's NEUROMARK® System leverages radiofrequency technology to address the underlying neural pathways contributing to chronic nasal symptoms. Neurent Medical is headquartered in Galway, Ireland. To learn more, visit: www.neuromark.com
Neurent Medical Raises €62.5 million in Oversubscribed Series C Financing
Neurent Medical, the pioneer behind NEUROMARK®, an innovative, minimally invasive solution to treat chronic rhinitis, today announced the successful close of its oversubscribed Series C financing, raising €62.5 million ($74 million) to drive commercial expansion, broaden clinical evidence, and advance its product and indication pipeline.
The financing was led by MVM Partners, with significant participation from Sofinnova Partners, and included continued support from existing investors EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners and Enterprise Ireland.
Chronic rhinitis affects millions of people worldwide and is characterized by persistent symptoms including nasal congestion, rhinorrhea (runny nose), sneezing and postnasal drip that can significantly diminish quality of life. NEUROMARK's proprietary Impedance Controlled Radiofrequency technology targets the overactive posterior nasal nerves (PNN) that drive these symptoms, providing clinicians with a differentiated and durable treatment option designed to address the root cause, not just manage symptoms.
"I am delighted to welcome MVM Partners and Sofinnova Partners to the Neurent Medical team, two global leaders in medtech investing," said CEO of Neurent Medical, Brian Shields. "This Series C financing will support our commercial expansion and help bring NEUROMARK to the patients and physicians who need it most."
Neurent Medical also welcomed Kyle Dempsey, Partner at MVM Partners, and Cedric Moreau, Partner at Sofinnova Partners, to its Board of Directors.
"Millions of patients suffer from chronic rhinitis, and posterior nasal nerve ablation represents a powerful tool to provide proven relief," said Kyle Dempsey. "In this rapidly emerging category, Neurent has set a new standard with a best-in-class solution, powered by a proprietary impedance control system that delivers real-time feedback, giving clinicians greater treatment confidence, control, and predictability during every procedure."
"Chronic rhinitis is a widespread and often overlooked condition affecting millions of patients with limited effective treatment options. Neurent Medical has developed a truly differentiated approach supported by a growing body of clinical evidence demonstrating meaningful and durable patient benefit," added Cedric Moreau. “We also see significant potential to expand this platform into additional indications, and we are confident in our partnership with Neurent Medical at this pivotal stage of commercial growth."
"Our mission since inception has been to meaningfully improve patients' lives while empowering ENT physicians with predictable, minimally invasive care," Shields continued. "In addition to expanding patient access, this investment will also enable further evidence generation across broader populations and support the continued development of our exciting pipeline offerings."
About NEUROMARK® and Neurent Medical
Neurent Medical is dedicated to transforming the treatment landscape for chronic inflammatory sinonasal diseases. Its flagship NEUROMARK System utilizes proprietary Impedance Controlled Radiofrequency technology to gently disrupt hyperactive posterior nasal nerves, delivering durable symptom relief from chronic rhinitis with minimal downtime and a strong safety profile.
Headquartered in Galway, Ireland, with U.S. operations in Braintree, Massachusetts, Neurent is advancing both scientific evidence and clinical adoption to establish a new standard of care in chronic rhinitis management. Learn more at www.neuromark.com.
About MVM Partners
MVM has invested in high-growth healthcare businesses since 1997. With teams in Boston, London, and the San Francisco Bay Area, MVM has a broad, global investment outlook spanning medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and other sectors of healthcare. More information can be found at www.mvm.com.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners manages over €4 billion in assets. For more information, please visit: www.sofinnovapartners.com.
Exciva raises €51 million ($59m) in Series B funding round
Exciva GmbH, a biopharmaceutical company developing novel therapeutic compounds for the treatment of neuropsychiatric conditions, today announces the closing of a €51 million ($59m) Series B financing round. Gimv and EQT Life Sciences co-led the round. Additional participants included new investors Fountain Healthcare Partners, LifeArc Ventures, Carma Fund and Modi Ventures, as well as existing investors Andera Partners and LBBW.
The proceeds will primarily fund a phase 2 study evaluating Deraphan’s therapeutic potential for treating agitation in patients with Alzheimer’s disease (AD). Deraphan is the combination of two clinically validated products, including one novel chemical entity (NCE), which have demonstrated activity in the CNS field, with the potential to offer better efficacy and risk/benefit ratio than existing therapies. The clinical trial will be conducted in Europe, the UK, the US and Canada. A phase 1 trial with Deraphan has been successfully completed and showed that the combination is safe and well-tolerated.
Following the Series B, the board of directors will be composed of Raphaël Wisniewski (Andera Partners), Philip Scheltens (EQT Life Sciences), Andreas Jurgeit (Gimv), Aidan King (Fountain Healthcare), Vikram Sudarsan (independent Board member) and François Conquet (CEO).
“We are delighted that we could attract funding from both existing and new investors. This confirms that our product is highly promising,” said François Conquet, CEO of Exciva. “If the results of the phase 2 trial are positive, it will be a significant step forward in symptomatic treatment options for patients with Alzheimer’s disease.”
“Exciva’s therapy for agitation in Alzheimer’s disease is highly differentiated, addressing significant shortcomings in the current standard of care and other products under development,” said Andreas Jurgeit, PhD, partner at Gimv. “We are pleased to collaborate with the Exciva team - backed by decades of expertise in neuropsychiatry drug development, including approved therapies - to transform care for this challenging aspect of dementia.”
“This investment illustrates the potential of Exciva to bring an exciting innovation into a therapeutic area where Alzheimer’s patients have limited or no treatment options,” added Philip Scheltens, MD, PhD, partner at EQT Life Sciences. “We are delighted to co-lead this financing to realize Exciva’s potential, which stands out for both the quality of its science and the expertise of the team. We look forward to bringing this new therapy to patients.”
Julia Braun and her team at Baker McKenzie provided legal advice on the financing to the new investors.
About agitation in Alzheimer’s disease
The behavioral and psychological symptoms of Alzheimer’s disease (AD) dementia can be severe and demanding on caregivers. These include agitation, aggression, sleep disorders, irritability, depression, anxiety and hallucinations. The prevalence of AD, and its associated behavioral and psychological symptoms, is growing in aging societies. If nothing is done in the meantime, the global dementia population is projected to grow from ~50 million today to over 150 million by 2050. Agitation is highly prevalent in and persistently associated with patients with AD. Epidemiological studies have revealed that, on average, about 40% of AD patient admissions reported agitation. It is estimated that more than 70% of people with AD dementia develop agitation at some point during the illness. As of today, only a few drugs are available to treat these symptoms; many carry significant side effects and boxed warnings, limiting their use.
About Exciva
Exciva is a biopharmaceutical company founded in 2016 by Drs. Anton Bespalov, Hans Moebius and Rao Vepachedu to address neuropsychiatric symptoms in Alzheimer’s disease dementia and other brain disorders. Exciva uses its powerful discovery potential, which has led to the combination of two CNS-active compounds to treat agitation in patients living with Alzheimer’s disease dementia. Exciva is based in Heidelberg, Germany. www.exciva.com
Haemonetics Acquires Vivasure Medical Limited
Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced the acquisition of Vivasure Medical Limited (Vivasure), a Galway, Ireland-based company pioneering next-generation technology for percutaneous vessel closure.
Vivasure's PerQseal® Elite system uses a proprietary bioabsorbable patch to seal large-bore (up to 26 F) arteriotomies and venotomies from inside the vessel, offering a sutureless, fully absorbable solution for structural heart and endovascular procedures. In 2025, Vivasure submitted a Premarket Approval application to the U.S. FDA for the PerQseal Elite arterial closure system and received CE Mark approval in Europe for both arterial and venous indications. Results from the prospective, single-arm, multi-center ELITE arterial study demonstrated ease of use with no need for pre-close, with 0% major complications at thirty-day follow-up, and immediate median time to hemostasis1.
The acquisition includes an upfront cash payment of €100 million, or approximately €52 million net of the value of certain previous investments and other loans made by Haemonetics to Vivasure as well as other customary closing adjustments, and up to an additional €85 million in contingent consideration based on sales growth and the achievement of certain other milestones, also subject to adjustment based on the value of certain prior investments and loan amounts. Haemonetics financed this transaction through available cash on hand.
"Acquiring Vivasure expands Haemonetics' complete range of closure devices with new and clinically differentiated technology to bolster our presence in the large-bore closure market and our impact in fast-growing structural heart and endovascular procedures," said Ken Crowley, Vice President & General Manager, Interventional Technologies at Haemonetics. "With strong clinical performance and safety data, PerQseal Elite positions us for increased leadership in advanced closure, as we leverage our commercial scale and operational synergies to deliver increased value to physicians and hospitals."
"We're extremely proud of the progress made in advancing closure technology, and grateful to the clinicians, employees, board members, investors and government bodies who supported Vivasure's mission. Joining Haemonetics provides the global scale and resources to accelerate the availability of PerQseal Elite and bring its clinical benefits to more physicians and patients worldwide," said Andrew Glass, Chief Executive Officer of Vivasure Medical Limited.
About Haemonetics
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit www.haemonetics.com.
About Vivasure Medical Limited
Based in Galway, Ireland, Vivasure is focused on the development of advanced polymer implants and delivery systems, primarily focused on minimally invasive vessel closure in cardiology, interventional radiology and vascular surgery. Vivasure operates a fully integrated R&D and ISO 13485 certified manufacturing facility.
PerQseal and PerQseal Elite are not available for sale in the United States. For more information, please visit www.vivasuremedical.com.
Mainstay Medical Announces Coverage Recommendation from the International Society for the Advancement of Spine Surgery (ISASS) for ReActiv8
Mainstay Medical Holdings plc today announced that the International Society for the Advancement of Spine Surgery (ISASS) has issued recommendations and coverage criteria for the use of restorative neurostimulation for the treatment of chronic mechanical low back pain associated with multifidus muscle dysfunction. ReActiv8® restorative neurostimulation is the only therapy approved in the United States, Europe and Australia for this indication.
The Statement, which affirms ISASS’ support for coverage by payers of implantable restorative neurostimulation in appropriately selected patients, was published in the December issue of the International Journal of Spine Surgery and can be accessed here: https://www.ijssurgery.com/content/early/2025/12/10/8833.
The Statement reflects the growing body of clinical evidence supporting the use of ReActiv8, as well as recent developments in diagnostic coding and reimbursement pathways since ISASS’ 2023 Statement on Restorative Neurostimulation for Chronic Mechanical Low Back Pain Resulting from Neuromuscular Instability. Key updates include: published five-year results from the pivotal randomized clinical trial; published one-year results from a second randomized clinical trial demonstrating ReActiv8’s superiority over standard of care; evidence from multiple real-world studies; the introduction of the new ICD-10 code M62.85: dysfunction of the multifidus muscles, lumbar region; and payer trends, including the recent establishment by Anthem Blue Cross Blue Shield of favorable coverage for ReActiv8.
“ISASS has a well-established history of supporting evidence-based technologies for patients with spine disease. The evidence for restorative neurostimulation - reactivating the multifidus muscle that drives mechanical low back pain - demonstrates meaningful improvements in pain, disability, and quality of life,” said Morgan P. Lorio, MD, ISASS Past President and Chair Emeritus, Coding & Reimbursement Task Force. “With new Level I data, the dedicated ICD-10 code, recent payer decisions, and the well-established clinical and economic significance of multifidus dysfunction, ISASS supports broader coverage and appropriate clinical adoption of restorative neurostimulation to improve outcomes and reduce the healthcare burden in this defined disease state.”
“We are pleased that ISASS has taken the lead by reviewing the totality of evidence, recognizing that ReActiv8 can benefit patients and payers,” stated Jason Hannon, Chief Executive Officer of Mainstay Medical. “We look forward to discussing our robust clinical and real-world evidence with health plans, with the goal of providing access to ReActiv8 for more patients seeking durable solutions for their mechanical chronic low back pain.”
MMI Wins FDA Clearance and Completes First U.S. Clinical Use of Robotic Microsurgical Dissection Instruments with Symani
First U.S. Patient Treated with NanoWrist Dissection Instruments, Marking Early Clinical Adoption and Portfolio Growth
JACKSONVILLE, FL — December 9, 2025 — MMI (Medical Microinstruments, Inc.), a robotics company dedicated to expanding treatment options and improving outcomes for patients with complex conditions, today announced that it received U.S. Food and Drug Administration 510(k) clearance for its NanoWrist® Scissors and Forceps indicated for soft tissue dissection. This clearance enables delicate tissue manipulation and dissection in robotic microsurgery, expanding the role of the Symani® Surgical System beyond anastomosis to include additional critical steps in complex surgery.
The first U.S. clinical use of the cleared instruments was recently completed at Tampa General Hospital (TGH), home to an established microsurgical robotics program. The lymphovenous bypass (LVB) procedure, leveraging the full capabilities of Symani, represents the world’s first fully robotic-assisted microsurgical operation from initial incision to skin closure.
Dr. Nicholas J. Panetta, MD, FACS, Chair of the Department of Plastic Surgery at the University of South Florida Morsani College of Medicine and Chief of the Plastic Surgery Institute at TGH, specializes in microvascular reconstructive plastic surgery. For the surgery, Symani and the NanoWrist Instrument Portfolio were utilized to complete a specialized microsurgical technique that redirects tiny lymphatic vessels to nearby veins, helping relieve swelling by restoring fluid drainage. He accessed the surgical site and prepared the lymphatic vessels and veins using the NanoWrist Scissors and Forceps for delicate tissue handling, precise dissection, and vessel preparation. The bypass was then performed with the NanoWrist SuperMicro Needle Holder Suture Cut and SuperMicro Dilator. All instruments in the portfolio offer seven degrees of freedom, delivering precise robotic capabilities and the full benefits of Symani’s motion scaling and tremor reduction features.
“Robotics will define the future of microsurgery, especially in lymphedema work where sub-millimeter precision is essential. I have been able to push the limits of microsurgery to treat some of the smallest and most delicate vessels, and the impact Symani is having on our patients has been transformative,” shared Dr. Panetta. “With robotic enabled dissection, I was able to complete a fully robotic LVB, from incision to closure, with unmatched precision, control and improved ergonomics. These tools are unlocking capabilities that extend beyond the limits of the human hand to support the best possible outcomes for patients.”
MMI’s dissection instruments are the world’s first and smallest fully wristed robotic instruments designed specifically for dissection in open microsurgery. The NanoWrist Scissors and Forceps are designed to preserve tissue integrity and reduce vessel trauma to help improve patient outcomes. This level of precision and control is especially critical in complex procedures such as surgical lymphatic repair, perforator-to-perforator reconstruction, and cancer-related head & neck reconstruction.
“As we continue to evolve Symani, the first dissection instruments are a critical step in that mission,” said Mark Toland, CEO of MMI. “The addition of these capabilities to our platform is game-changing in supermicrosurgical procedures where extreme precision for the smallest vessels is essential. We will continue to develop technologies that advance the future of microsurgery with Symani and transform microsurgical care and countless lives worldwide.”
These achievements follow a string of meaningful milestones for MMI and the microsurgical sector this year, including the company’s advancement into neurosurgery, launching the largest U.S. prospective clinical trial in robotic microsurgery, additional expanded technological and digital surgery capabilities, and gaining reimbursement support for select procedures.
For more information about Symani and the dissection instruments, visit www.mmimicro.com.